Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thanks to sunny skies brightening the Pharmalot campus. After all, a few birds can be heard chirping and a crisp breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy …

Food and Drug Administration scientists say the Johnson & Johnson (JNJ) Covid-19 single-shot vaccine is effective and prevents hospitalizations from the disease, STAT reports. The company also revealed new, encouraging data showing its shot may do a better-than-expected job at protecting patients against new variants of the virus. At the same time, FDA experts say study data, results of which were originally made public in a Jan. 29 press release, includes insufficient information to draw conclusions on efficacy in people older than 75.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If memory serves, this will be India’s’ third push to do a reset of the supply chain with China in the last 5 or 6 years. Perhaps they will succeed this time?

Comments are closed.